德康医疗 DXCM 深 沪
等待开盘 03-26 09:30:00 美东时间
67.09
+0.490
+0.74%
华盛通- 最 高68.09
- 今 开67.22
- 成交量 138.72万股
- 最 低 65.55
- 昨 收 66.60
- 总市值 258.21亿
- 52周最高 89.98
- 市盈率 静 32.11
- 换手率 0.36%
- 52周最低 54.11
- 委 比 79.07%
- 总股本 3.85亿
- 历史最高 164.863
- 量 比 0.37
- 振 幅 3.81%
- 历史最低 1.6875
- 每 手 1
- 风险率 8.31%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多BUZZ-U.S. STOCKS ON THE MOVE-DexCom, Ocugen, Estee Lauder
BUZZ-U.S. STOCKS ON THE MOVE-DexCom, Ocugen, Estee Lauder Workspace search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 March 24 (Reuters) - U.S. stock index futures pointed to a lower open on
03-24 21:10
US STOCKS-Wall Street futures subdued as Middle East uncertainty tempers relief rally
US STOCKS-Wall Street futures subdued as Middle East uncertainty tempers relief rally Futures: Dow down 0.1%, S&P 500 & Nasdaq flat Jefferies gains on report Japan's SMFG plans possible takeover Barclays raises year-end target for S&P 500 to 7,650 from 7,400 Updates with prices By Purvi Agarwal and
03-24 19:20
迈瑞医疗前高管创立的“麦科田”二次递表港交所，2025年扭亏为盈
深圳麦科田生物医疗技术股份有限公司于2026年3月11日第二次向港交所递交招股书，计划在香港主板上市，联席保荐人为摩根士丹利和华泰国际。公司创始人刘杰曾担任迈瑞医疗高管，属于"迈瑞系"创业代表。麦科田专注于生命支持、微创介入和体外诊断三大领域，通过自主创新和战略收购迅速扩张。2025年公司收入16.19亿元，同比增长15.71%，净利润0.51亿元，成功扭亏为盈。公司通过收购Penlon（英国）和唯德康医疗，补齐产品线并拓展销售渠道。目前产品销往140多个国家和地区，覆盖中国6000多家医院。高瓴、深创投等机构入股，显示市场对其高度认可。
03-12 17:17
美股大行评级 | 甲骨文绩后分歧大！小摩上调评级至"超配"，目标价缺降至210美元；科尔士百货、AVAV、Blend Labs、Domo遭多家大行下调评级
今日重点评级关注：LUCID CAPITAL MARKETS：上调INmune Bio评级至"买入" 目标价从2美元升至9美元；Clear Street：维持MoonLake Immunotherapeutics Class A"买入"评级，目标价从45美元升至70美元
03-12 12:34
Citigroup Maintains Buy on DexCom, Raises Price Target to $84
Citigroup analyst Joanne Wuensch maintains DexCom (NASDAQ:DXCM) with a Buy and raises the price target from $77 to $84.
03-11 23:33
龙头械企，官宣停产！
近期，作为全球连续血糖监测（CGM）领域的龙头企业，德康医疗（Dexcom）动作频频，一则停产通知引发行业广泛关注。 目前，德康医疗已开始陆续通知患者，将于2...
03-11 17:47
Dexcom Presents New G7 Registry Data Showing A1C And Weight Management Improvements In Non-Insulin Type 2 Diabetes Patients At ATTD 2026
New registry study data shows that long-term use of Dexcom G7 supports weight management and lowers A1C for people with Type 2 diabetes who aren't on insulin therapy1, reinforcing the need to broaden CGM access beyond
03-11 14:28
Dexcom to present data and product roadmap at ATTD 2026
Dexcom to present data and product roadmap at ATTD 2026 Dexcom will attend the Advanced Technologies and Treatments for Diabetes Conference in Barcelona on March 11-14, 2026, with event information at https://attd.kenes.com/ . Dexcom is scheduled to host a symposium, “Dexcom technology, innovation a
03-11 14:01
Dexcom real-world study links 1-year G7 use to lower HbA1c in non-insulin Type 2 diabetes
Dexcom real-world study links 1-year G7 use to lower HbA1c in non-insulin Type 2 diabetes Dexcom said it will present new clinical and real-world evidence on its continuous glucose monitoring (CGM) technology at the Advanced Technologies and Treatments for Diabetes Conference in Barcelona, March 11–
03-11 14:00
